These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 39405909)

  • 1. Sensitizing cholangiocarcinoma to chemotherapy by inhibition of the drug-export pump MRP3.
    Asensio M; Briz O; Herraez E; Perez-Silva L; Espinosa-Escudero R; Bueno-Sacristan D; Peleteiro-Vigil A; Hammer H; Pötz O; Kadioglu O; Banales JM; Martinez-Chantar ML; Avila MA; Macias RIR; Efferth T; Marin JJG; Lozano E
    Biomed Pharmacother; 2024 Nov; 180():117533. PubMed ID: 39405909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression.
    Lozano E; Asensio M; Perez-Silva L; Banales JM; Briz O; Marin JJG
    Hepatology; 2020 Sep; 72(3):949-964. PubMed ID: 31863486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.
    Tepsiri N; Chaturat L; Sripa B; Namwat W; Wongkham S; Bhudhisawasdi V; Tassaneeyakul W
    World J Gastroenterol; 2005 May; 11(18):2748-53. PubMed ID: 15884115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma.
    Lampis A; Carotenuto P; Vlachogiannis G; Cascione L; Hedayat S; Burke R; Clarke P; Bosma E; Simbolo M; Scarpa A; Yu S; Cole R; Smyth E; Mateos JF; Begum R; Hezelova B; Eltahir Z; Wotherspoon A; Fotiadis N; Bali MA; Nepal C; Khan K; Stubbs M; Hahne JC; Gasparini P; Guzzardo V; Croce CM; Eccles S; Fassan M; Cunningham D; Andersen JB; Workman P; Valeri N; Braconi C
    Gastroenterology; 2018 Mar; 154(4):1066-1079.e5. PubMed ID: 29113809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide.
    Ortiz-Rivero S; Peleteiro-Vigil A; Abete L; Lozano E; Hammer HS; Giacomo SD; Abad M; Boix L; Forner A; Reig M; Macias RIR; Pötz O; Marin JJG; Briz O
    Biomed Pharmacother; 2024 Jan; 170():116038. PubMed ID: 38141281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
    Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H
    Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines.
    Dokduang H; Jamnongkarn W; Promraksa B; Suksawat M; Padthaisong S; Thanee M; Phetcharaburanin J; Namwat N; Sangkhamanon S; Titapun A; Khuntikeo N; Klanrit P; Loilome W
    Drug Des Devel Ther; 2020; 14():2319-2334. PubMed ID: 32606601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy.
    Lozano E; Macias RIR; Monte MJ; Asensio M; Del Carmen S; Sanchez-Vicente L; Alonso-Peña M; Al-Abdulla R; Munoz-Garrido P; Satriano L; O'Rourke CJ; Banales JM; Avila MA; Martinez-Chantar ML; Andersen JB; Briz O; Marin JJG
    Hepatology; 2019 Oct; 70(4):1246-1261. PubMed ID: 30972782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
    Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
    Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells.
    Seubwai W; Vaeteewoottacharn K; Kraiklang R; Umezawa K; Okada S; Wongkham S
    Oncol Res; 2016 Jan; 23(1-2):21-8. PubMed ID: 26802647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ATO/miRNA-885-5p/MTPN axis induces reversal of drug-resistance in cholangiocarcinoma.
    Wang Y; Zhang W; Chen L; Chen W; Xu S; Tang L; Yang Y; Li Q; Jiang Q; Miao L
    Cell Oncol (Dordr); 2021 Aug; 44(4):907-916. PubMed ID: 34170484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanism of Spatholobi Caulis treatment for cholangiocarcinoma based on network pharmacology, molecular docking, and molecular dynamics simulation.
    Chen X; Sun B; Zeng J; Yu Z; Liu J; Tan Z; Li Y; Peng C
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Aug; 397(8):5789-5806. PubMed ID: 38321212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models.
    Awasthi N; Darman L; Schwarz MA; Schwarz RE
    J Cell Mol Med; 2024 Sep; 28(17):e18585. PubMed ID: 39223878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MBD2 regulates the progression and chemoresistance of cholangiocarcinoma through interaction with WDR5.
    Wang D; Chen J; Wu G; Xiong F; Liu W; Wang Q; Kuai Y; Huang W; Qi Y; Wang B; He R; Chen Y
    J Exp Clin Cancer Res; 2024 Sep; 43(1):272. PubMed ID: 39350229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion.
    Kawano S; Kawada MI; Fukushima S; Arai Y; Shibata T; Miyano SW
    Anticancer Res; 2024 Jun; 44(6):2393-2406. PubMed ID: 38821585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
    Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
    J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-lysyl oxidase inhibition disrupts fibroinflammatory tumor stroma, rendering cholangiocarcinoma susceptible to chemotherapy.
    Burchard PR; Ruffolo LI; Ullman NA; Dale BS; Dave YA; Hilty BK; Ye J; Georger M; Jewell R; Miller C; De Las Casas L; Jarolimek W; Perryman L; Byrne MM; Loria A; Marin C; Chávez Villa M; Yeh JJ; Belt BA; Linehan DC; Hernandez-Alejandro R
    Hepatol Commun; 2024 Aug; 8(8):. PubMed ID: 39101793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Actinidia arguta (Hardy Kiwi) Root Extract Exerts Anti-cancer Effects via Mcl-1-Mediated Apoptosis in Cholangiocarcinoma.
    Zhao X; Wen F; Wang W; Lu Z; Guo Q
    Nutr Cancer; 2019; 71(2):246-256. PubMed ID: 30633583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma.
    Ito Y; Yamada D; Kobayashi S; Sasaki K; Iwagami Y; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
    Cancer Lett; 2024 Jul; 595():216997. PubMed ID: 38801887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of chloride channel-3 enhances cisplatin sensitivity of cholangiocarcinoma cells though inhibiting autophagy.
    Han Y; Zhou Y; Zhou L; Jia X; Yu X; An X; Shi Z
    Can J Physiol Pharmacol; 2022 Jul; 100(7):584-593. PubMed ID: 35413227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.